Oruka Therapeutics (NASDAQ:ORKA) Reaches New 52-Week High – What’s Next?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) shares hit a new 52-week high during mid-day trading on Friday . The company traded as high as $91.12 and last traded at $90.60, with a volume of 4547354 shares changing hands. The stock had previously closed at $86.63.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ORKA. Guggenheim set a $200.00 target price on shares of Oruka Therapeutics and gave the stock a “buy” rating in a report on Monday, April 27th. Barclays raised their target price on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research note on Monday, April 27th. Stifel Nicolaus lifted their price target on shares of Oruka Therapeutics from $47.00 to $72.00 and gave the company a “buy” rating in a report on Friday, March 13th. Piper Sandler reiterated an “overweight” rating and issued a $180.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. Finally, UBS Group increased their price objective on shares of Oruka Therapeutics from $75.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Oruka Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $131.30.

Oruka Therapeutics Trading Up 4.6%

The firm has a market cap of $5.46 billion, a P/E ratio of -46.70 and a beta of -0.26. The business has a 50-day moving average price of $66.95 and a 200-day moving average price of $47.33.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.04. On average, equities analysts anticipate that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current fiscal year.

Insider Buying and Selling at Oruka Therapeutics

In other Oruka Therapeutics news, SVP Arjun Agarwal sold 1,587 shares of the company’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $80.95, for a total transaction of $128,467.65. Following the completion of the sale, the senior vice president owned 15,312 shares in the company, valued at $1,239,506.40. This represents a 9.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Carl Dambkowski sold 12,583 shares of the stock in a transaction on Friday, June 12th. The shares were sold at an average price of $70.11, for a total value of $882,194.13. Following the sale, the director directly owned 38,743 shares in the company, valued at $2,716,271.73. This trade represents a 24.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 185,407 shares of company stock worth $11,636,307. 23.49% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc purchased a new stake in shares of Oruka Therapeutics during the 2nd quarter worth $28,000. BNP Paribas Financial Markets boosted its position in Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock valued at $31,000 after purchasing an additional 2,306 shares in the last quarter. Royal Bank of Canada grew its stake in Oruka Therapeutics by 47.2% in the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after purchasing an additional 365 shares during the last quarter. Los Angeles Capital Management LLC purchased a new position in Oruka Therapeutics in the fourth quarter valued at about $37,000. Finally, PNC Financial Services Group Inc. bought a new position in Oruka Therapeutics in the third quarter worth about $39,000. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.